UPDATE 2-Bristol-Myers recalls Avalide blood pressure drug

Thu, Jan 13 2011

* 64 million tablets recalled in U.S., Puerto Rico



* Second recall of drug in less than four months



* Recall over potential for reduced efficacy (Adds affected doses, background, company comment, share price)



By Bill Berkrot

NEW YORK, Jan 13 (Reuters) - Bristol-Myers Squibb Co (BMY.N: Quote, Profile, Research, Stock Buzz) said it has recalled 64 million tablets of the blood pressure medicine Avalide in the United States and Puerto Rico due to the potential for reduced effectiveness.



The move, which Bristol-Myers said was undertaken as a precautionary measure, marked the second major recall in less than four months of the medicine co-marketed with French drugmaker Sanofi-Aventis (SASY.PA: Quote, Profile, Research, Stock Buzz).



In September, Bristol-Myers recalled 62 lots, or 60 million tablets, of the drug manufactured in Puerto Rico. The new recall involved 65 lots of Avalide manufactured in plants in Humacal, Puerto Rico and Evansville, Indiana, the company said.



Avalide is a combination pill comprised of the drugs irbesartan, which is sold under the brand name Avapro, and hydrochlorothiazide, a generic diuretic.



The recall was not announced publicly but communicated via letters to wholesalers and healthcare professionals, Bristol-Myers said.



Reuters first learned of the recall from a doctor.



The problem detected was the same that led to the previous recall, a potential variability in levels of the less-soluble form of the active ingredient irbesartan.



As with the September recall, the problem suggests the possibility of reduced efficacy, although the company has not turned up evidence of reduced effectiveness, nor have there been any reports of safety problems or patient harm, Bristol-Myers spokeswoman Christina Trank said.



The affected Avalide doses were 150/12.5 milligrams, 300/12.5 mg, 300/25 mg and blister sample packs of 300/25 mg. The first number represents the irbesartan dose.



The recall did not involve stand-alone Avapro, the company said.



For the first nine months of 2010, Bristol-Myers reported combined worldwide sales of Avalide and Avapro of $924 million.



Since the September recall, Trank said the company had developed more sensitive testing methods to detect a less soluble form of the active ingredient and the new testing revealed the need for a further recall.



Patients who have purchased Avalide from the recalled lots can contact their prescribing doctor, pharmacy or Bristol-Myers customer relations, Trank said.



Bristol-Myers shares closed down 5 cents at $25.90 on the New York Stock Exchange. (Reporting by Bill Berkrot; additional reporting by Debra Sherman in Chicago; editing by Carol Bishopric)



© Thomson Reuters 2010. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.



Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.



This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to colleagues, clients or customers, use the Reprints tool at the top of any article or visit: www.reutersreprints.com.